Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Thromb Haemost ; 121(8): 992-1007, 2021 08.
Artigo em Inglês | MEDLINE | ID: mdl-34169495

RESUMO

BACKGROUND: One year after the declaration of the coronavirus disease 2019 (COVID-19) pandemic by the World Health Organization (WHO) and despite the implementation of mandatory physical barriers and social distancing, humanity remains challenged by a long-lasting and devastating public health crisis. MANAGEMENT: Non-pharmacological interventions (NPIs) are efficient mitigation strategies. The success of these NPIs is dependent on the approval and commitment of the population. The launch of a mass vaccination program in many countries in late December 2020 with mRNA vaccines, adenovirus-based vaccines, and inactivated virus vaccines has generated hope for the end of the pandemic. CURRENT ISSUES: The continuous appearance of new pathogenic viral strains and the ability of vaccines to prevent infection and transmission raise important concerns as we try to achieve community immunity against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) and its variants. The need of a second and even third generation of vaccines has already been acknowledged by the WHO and governments. PERSPECTIVES: There is a critical and urgent need for a balanced and integrated strategy for the management of the COVID-19 outbreaks organized on three axes: (1) Prevention of the SARS-CoV-2 infection, (2) Detection and early diagnosis of patients at risk of disease worsening, and (3) Anticipation of medical care (PDA). CONCLUSION: The "PDA strategy" integrated into state policy for the support and expansion of health systems and introduction of digital organizations (i.e., telemedicine, e-Health, artificial intelligence, and machine-learning technology) is of major importance for the preservation of citizens' health and life world-wide.


Assuntos
COVID-19/epidemiologia , COVID-19/prevenção & controle , Saúde Pública , COVID-19/diagnóstico , Teste para COVID-19/métodos , Vacinas contra COVID-19/uso terapêutico , Gerenciamento Clínico , Humanos , Programas de Imunização/métodos , Pandemias/prevenção & controle , Saúde Pública/métodos , Medição de Risco , SARS-CoV-2/isolamento & purificação
2.
Int J Stroke ; 13(4): 420-443, 2018 06.
Artigo em Inglês | MEDLINE | ID: mdl-29171361

RESUMO

The 2017 update of The Canadian Stroke Best Practice Recommendations for the Secondary Prevention of Stroke is a collection of current evidence-based recommendations intended for use by clinicians across a wide range of settings. The goal is to provide guidance for the prevention of ischemic stroke recurrence through the identification and management of modifiable vascular risk factors. Recommendations include those related to diagnostic testing, diet and lifestyle, smoking, hypertension, hyperlipidemia, diabetes, antiplatelet and anticoagulant therapies, carotid artery disease, atrial fibrillation, and other cardiac conditions. Notable changes in this sixth edition include the development of core elements for delivering secondary stroke prevention services, the addition of a section on cervical artery dissection, new recommendations regarding the management of patent foramen ovale, and the removal of the recommendations on management of sleep apnea. The Canadian Stroke Best Practice Recommendations include a range of supporting materials such as implementation resources to facilitate the adoption of evidence to practice, and related performance measures to enable monitoring of uptake and effectiveness of the recommendations. The guidelines further emphasize the need for a systems approach to stroke care, involving an interprofessional team, with access to specialists regardless of patient location, and the need to overcome geographic barriers to ensure equity in access within a universal health care system.


Assuntos
Prática Profissional/normas , Acidente Vascular Cerebral/prevenção & controle , Consumo de Bebidas Alcoólicas/prevenção & controle , Doenças da Aorta/prevenção & controle , Fibrilação Atrial/prevenção & controle , Peso Corporal/fisiologia , Estenose das Carótidas/prevenção & controle , Angiografia por Tomografia Computadorizada , Anticoncepcionais Orais/efeitos adversos , Angiopatias Diabéticas/prevenção & controle , Dieta Saudável , Terapia de Reposição de Estrogênios/efeitos adversos , Exercício Físico/fisiologia , Forame Oval Patente/cirurgia , Estilo de Vida Saudável , Insuficiência Cardíaca/prevenção & controle , Humanos , Hiperlipidemias/prevenção & controle , Hipertensão/prevenção & controle , Drogas Ilícitas/efeitos adversos , Arteriosclerose Intracraniana/prevenção & controle , Ataque Isquêmico Transitório/prevenção & controle , Angiografia por Ressonância Magnética , Imagem Multimodal , Medição de Risco , Fatores de Risco , Prevenção Secundária , Fumar/efeitos adversos , Ultrassonografia
3.
Am J Hematol ; 87 Suppl 1: S141-5, 2012 May.
Artigo em Inglês | MEDLINE | ID: mdl-22473649

RESUMO

The new oral anticoagulants dabigatran, rivaroxaban and apixaban have advantages over warfarin which include no need for laboratory monitoring, less drug-drug interactions and less food-drug interactions. However, there is no established antidote for patients who are bleeding or require emergent surgery and there is a paucity of evidence to guide the clinical care during these situations. Members of thrombosis and anticoagulation groups participating in the Thrombosis and Hemostasis Summit of North America formulated expert opinion guidance for reversing the anticoagulant effect of the new oral anticoagulants and suggest: routine supportive care, activated charcoal if drug ingestion was within a couple of hours, and hemodialysis if feasible for dabigatran. Also, the pros and cons of the possible use of four factor prothrombin complex concentrate are discussed.


Assuntos
Antídotos/uso terapêutico , Inibidores dos Fatores de Coagulação Sanguínea/efeitos adversos , Fatores de Coagulação Sanguínea/uso terapêutico , Carvão Vegetal/uso terapêutico , Inibidores do Fator Xa , Hemorragia/induzido quimicamente , Hemorragia/tratamento farmacológico , Trombina/antagonistas & inibidores , Administração Oral , Inibidores dos Fatores de Coagulação Sanguínea/uso terapêutico , Interações Medicamentosas , Monitoramento de Medicamentos/métodos , Hemorragia/sangue , Humanos , Guias de Prática Clínica como Assunto
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA